1 Recruiting
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer
Condition: Non-small Cell Lung Cancer
Interventions: Biological: Stimuvax; Biological: Placebo
2 Recruiting
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
Condition: Tumor Antigen-positive Non-Small Cell Lung Cancer
Interventions: Biological: GSK1572932A Antigen-Specific Cancer Immunotherapeutic; Biological: Placebo Control
3 Completed
A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)
Condition:Carcinoma, Non-Small Cell Lung
Interventions: Drug: Nexavar (Sorafenib, BAY43-9006) + carboplatin + paclitaxel; Drug: Carboplatin plus Paclitaxel
4 Completed
OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: Tarceva (erlotinib HCl, OSI-774 )
5 Terminated
Trial of Paclitaxel/Carboplatin + PF-3512676 vs Paclitaxel/Carboplatin Alone in Patients With Advanced Non-Small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: PF-3512676 + Paclitaxel + Carboplatin; Drug: Paclitaxel + Carboplatin
6 Completed
A Randomized Phase 3 Trial of Pemetrexed and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer
Condition: Non Small Cell Lung Carcinoma
Interventions: Drug: pemetrexed; Drug: gemcitabine; Drug: cisplatin
7 Completed
A Phase 3 Trial of LY900003 Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: LY900003
8 Active, not recruiting
Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer(FLEX)
Condition: Non Small Cell Lung Cancer
Interventions: Drug: cetuximab + cisplatin + vinorelbine; Drug: cisplatin + vinorelbine
9 Not yet recruiting
A Retrospective Study to Investigate the Current Situation of Biopsy Testing in Swedish Inoperable Non Small Cell Lung Cancer (NSCLC) Patients
Condition: Non Small Cell Lung Cancer
Intervention:
10 Active, not recruiting
A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
Conditions: Carcinoma; Non Small Cell Lung
Interventions: Drug: Aflibercept (AVE0005); Drug: Placebo
11 Recruiting
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Conditions: Melanoma; Non-small Cell Lung Cancer
Intervention: Procedure: Collection of tumor and blood samples
12 Recruiting
A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer NSCLC.
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Nexavar (Sorafenib, BAY43-9006); Drug: Placebo
13 Active, not recruiting
Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
Condition: Non-small Cell Lung Cancer (NSCLC)
Intervention: Drug: ABT-869
14 Recruiting
AVAPERL1 Study: A Study of Avastin (Bevacizumab) With or Without Pemetrexed as Maintenance Therapy After Avastin in First Line in Patients With Non-Squamous Non-Small Cell Lung Cancer
Condition: Non-small Cell Lung Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: pemetrexed; Drug: cisplatin
15 Completed
Iressa Versus Docetaxel (Taxotere)
Condition: Non-Small-Cell Lung Carcinoma
Interventions: Drug: Gefitinib; Drug: Docetaxel
16 Active, not recruiting
Study of Pemetrexed Versus Pemetrexed + Erlotinib as Treatment of Non Small Cell Lung Cancer
Condition: Non Small Cell Lung Cancer
Interventions: Drug: pemetrexed; Drug: erlotinib
17 Terminated
ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer
Condition: Non-small Cell Lung Cancer
Interventions: Drug: ASA404 in combination with carboplatin and paclitaxel; Drug: Placebo in combination with carboplatin and paclitaxel
18 Recruiting
A Study of Pemetrexed and Bevacizumab for Patients With Advanced Non Small Cell Cancer
Condition: Non Small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Cisplatin; Drug: Bevacizumab
19 Recruiting
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Condition: Non-small Cell Lung Cancer
Intervention: Drug: erlotinib [Tarceva]
20 Active, not recruiting
A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab; Drug: erlotinib HCl; Drug: placebo
21 Active, not recruiting
Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients
Conditions: Non Small Cell Lung Cancer; Lung Cancer
Interventions: Drug: Vandetanib; Drug: Pemetrexed
22 Completed
Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative Gemcitabine-Cisplatin in Early Stages NSCLC
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: gemcitabine; Drug: Cisplatin; Procedure: surgery
23 Completed
MATER Study: A Study of Metronidazole Cream in the Prevention and Treatment of Tarceva (Erlotinib)-Associated Rash
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: erlotinib [Tarceva]; Drug: metronidazole actavis 1% topical cream
24 Active, not recruiting
Effect of Celecoxib on Survival in Patients With Advanced Non-Small Cell Lung Cancer Receiving Chemotherapy
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Celecoxib; Drug: Placebo
25 Recruiting
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Pemetrexed; Drug: BIBF1120; Drug: Folic Acid; Drug: BIBF1120 placebo
26 Active, not recruiting
A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
Condition: Non-small Cell Lung Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Platinum-based chemotherapy
27 Active, not recruiting
Study of Enzastaurin Versus Placebo in the Treatment of Patients With Brain Metastases of Lung Cancer, After Whole Brain Radiation Therapy
Conditions: Non Small Cell Lung Cancer; Small Cell Lung Cancer
Interventions: Drug: enzastaurin; Drug: placebo
28 Active, not recruiting
Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin’s Lymphoma
Condition: Lymphoma
Interventions: Procedure: immunoscintigraphy; Radiation: technetium Tc 99m epratuzumab
29 Active, not recruiting
Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin’s Lymphoma
Condition: Lymphoma
Interventions: Procedure: immunoscintigraphy; Radiation: technetium Tc 99m epratuzumab
30 Terminated
The Effect on Mucosal Healing With Pentasa Sachet in Mild to Moderate Active ”Drug: Crohn’s Disease”
Condition: Crohn’s Disease
Intervention: Drug: Mesalazine (Mesalamine)
31 Completed
Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate
Conditions: Atrial Fibrillation; Cerebrovascular Accident
Interventions: Drug: Dabigatran etex; Drug: Warfarin
32 Recruiting
Diagnosis of Intestinal Motility by Image Analysis Using Capsule Endoscopy
Condition: Intestinal Abnormalities
Intervention: Device: PillCam SB2
33
Active, not recruiting
Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation
Conditions: Atrial Fibrillation; Stroke
Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939); Drug: Warfarin
34 Recruiting
Compliance With Treatment For Patients With Hyperlipidemia
Condition: Hyperlipidemia
Intervention: Device: Lipid Self Test
35 Active, not recruiting
Evaluation of Weekly Subcutaneous Biotinylated Idraparinux Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
Condition: Atrial Fibrillation
Interventions: Drug: SSR126517E ”biotinylated idraparinux”; Drug: warfarin
36 Recruiting
Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results – A Long Term Evaluation
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: liraglutide; Drug: placebo
37 Completed
Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer’s Disease
Condition: Alzheimer’s Disease
Interventions: Drug: Rosiglitazone Extended Release 2mg; Drug: Rosiglitazone Extended Release 8mg; Other: Placebo
38 Completed
Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery
Conditions: Deep Vein Thrombosis; Pulmonary Embolism
Interventions: Drug: Enoxaparin + Placebo; Drug: Apixaban + Placebo
39 Completed
Long-Term Safety Evaluation Of Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
Conditions: Bowel Dysfunction; Constipation
Intervention: Drug: alvimopan
40 Active, not recruiting
Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin’s Lymphoma
Condition: Non-Hodgkin’s Lymphoma
Interventions: Drug: Bortezomib + Rituximab; Drug: Rituximab
41 Active, not recruiting
Evaluation of Capsule Endoscopy in Patients With Suspected Crohn’s Disease
Condition: Crohn’s Disease
Intervention: Device: Capsule Endoscopy
42 Completed
Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer
Condition: Prostatic Neoplasms
Intervention: Drug: Atrasentan
43 Active, not recruiting
Evaluation of Cipro Inhale in Patients With Non-cystic Fibrosis Bronchiectasis
Condition:Bronchiectasis
Interventions:Drug: Cipro (Ciprofloxacin, BAYQ3939); Drug: Placebo
44 Active, not recruiting
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Conditions:Atherosclerosis; Cardiovascular Disease; Coronary Heart Disease; CV Risk
Interventions:Drug: Darapladib; Drug: Placebo
45 Active, not recruiting
E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events
Conditions: Secondary Hyperparathyroidism; Chronic Kidney Disease
Interventions: Drug: Cinacalcet; Drug: Sensipar (Cinacalcet HCl); Drug: Placebo
46 Completed
A Comparison of AZD6140 and Clopidogrel in Patients With Acute Coronary Syndrome
Condition: Acute Coronary Syndrome
Interventions: Drug: AZD6140; Drug: Clopidogrel
47 Completed
Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Deep-Vein Thrombosis Without Symptomatic Pulmonary Embolism: Einstein-DVT Evaluation
Condition: Venous Thrombosis
Interventions: Drug: Xarelto (Rivaroxaban, BAY59-7939); Drug: Enoxaparin followed by VKA
48 Recruiting
Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Pulmonary Embolism With Or Without Symptomatic Deep-Vein Thrombosis: Einstein-PE Evaluation
Condition: Pulmonary Embolism
Interventions: Drug: Xarelto (Rivaroxaban, BAY59-7939); Drug: Enoxaparin followed by VKA
49 Completed
Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery
Conditions:Deep Vein Thrombosis; Pulmonary Embolism
Interventions: Drug: Enoxaparin + Placebo; Drug: Apixaban + Placebo
50 Active, not recruiting
RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RE-LY Trial
Condition:Atrial Fibrillation
Interventions:Drug: dabigatran dose 2; Drug: dabigatran dose 1
51 Active, not recruiting
Double-blind Study of Denosumab Compared With Zoledronic Acid in the Treatment of Bone Metastases in Subjects With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
Condition: Bone Metastases
Interventions: Biological: Denosumab; Drug: Zoledronic Acid
52 Completed
Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism DVT and Pulmonary Embolism (PE); a Study of BAY 59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement
Condition:Venous Thromboembolism
Interventions: Drug: Rivaroxaban (BAY59-7939); Drug: Enoxaparin
53 Completed
A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Non-steroidal Therapy.
Condition: Asthma
Intervention: Drug: GW685698X
54Completed
Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/Glibenclamide
Condition: Non-Insulin-Dependent Diabetes Mellitus
Interventions: Drug: Rosiglitazone; Drug: glyburide; Drug: metformin
55 Recruiting
First Line Hepato Cellular Carcinoma (HCC)
Condition: Hepato Cellular Carcinoma (HCC)
Interventions: Drug: Brivanib; Drug: Placebo; Drug: Sorafenib
56 Recruiting
Study Evaluating the Efficacy and Safety of Bapineuzumab in Alzheimer Disease Patients
Condition: Alzheimer Disease
Interventions: Drug: bapineuzumab; Drug: placebo
57 Completed
Has Results
”REDUCE” – A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk
Condition: Prostate Cancer
Interventions: Drug: Placebo; Drug: Dutasteride
58 Active, not recruiting
The Protégé Study – Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus
Condition: Type 1 Diabetes Mellitus
Interventions: Drug: Teplizumab; Other: Placebo
59 Completed
A Study of PS-341 Given to Patients With Multiple Myeloma Who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039
Condition: Multiple Myeloma
Intervention: Drug: bortezomib
60 Terminated
Open-Label Extension Study Of Rosiglitazone XR As Adjunctive Therapy In Subjects With Mild-to-Moderate Alzheimers
Condition:Mild-to-moderate Alzheimers Disease
Intervention:Drug: Rosiglitazone XR
61 Completed
Has Results
Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve)
Condition: Congestive Heart Failure
Interventions: Drug: Irbesartan; Drug: Placebo
62 Enrolling by invitation
Extension Study to Assess Long Term Safety, Tolerability and Efficacy of Valsartan and Enalapril Combined and Alone in Children With Hypertension
Condition: Hypertension
Intervention: Drug: Valsartan, enalapril
63 Active, not recruiting
A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer
Condition: Thyroid Cancer
Intervention: Drug: AMG 706
64 Recruiting
Golimumab in Rheumatoid Arthritis Patients With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)
Conditions: Arthritis; Arthritis, Rheumatoid; Autoimmune Diseases
Interventions: Drug: golimumab; Drug: golimumab or placebo
65 Completed
Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients
Condition: Hemophilia A
Intervention: Drug: Antihemophilic factor, recombinant, manufactured protein-free (rAHF-PFM)
66 Completed
Once – Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study
Condition: Venous Thromboembolism
Interventions: Drug: Xarelto (Rivaroxaban, BAY59-7939); Drug: Placebo
67 Recruiting
Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTX
Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550; Drug: Disease-modifying antirheumatic drug
68 Active, not recruiting
A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.
Condition: Bone Metastases in Subjects With Advanced Breast Cancer
Interventions: Biological: Denosumab; Drug: Zoledronic Acid
69 Recruiting
Efficacy of Acetylcysteine in Patients Undergoing Surgery for Otosclerosis
Condition: Otosclerosis
Interventions: Drug: Acetylcysteine; Drug: Placebo (NaCl)
70Terminated
Has Results
The Effect of Somatropin Treatment in Adult Patients on Chronic Dialysis
Condition: End-stage Renal Disease (ESRD)
Interventions: Drug: somatropin; Drug: placebo
71 Completed
Dose Ranging Study With LT, Monotherapy, PPAR
Condition: Diabetes Mellitus II
Intervention: Drug: Muraglitazar
72 Active, not recruiting
A Study of Tocilizumab in Patients With Active Systemic Juvenile Idiopathic Arthritis
Condition: Juvenile Idiopathic Arthritis
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: Placebo; Drug: NSAIDs + methotrexate
73 Recruiting
Joint Status in Subjects With Severe Hemophilia A in Relation to Different Treatment Regimens
Condition: Hemophilia A
Intervention: Procedure: No Drug
74 Active, not recruiting
Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients
Condition: Cytomegalovirus Infections
Interventions: Drug: maribavir; Other: placebo
75 Recruiting
Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment
Condition: Liver Cancer
Interventions: Drug: Brivanib; Drug: Placebo
76 Terminated
GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer
Condition: Prostate Cancer
Interventions: Biological: Immunotherapy with allogeneic prostate vaccine; Drug: Chemotherapy (Taxotere and prednisone)
77 Recruiting
EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer
Condition: Breast Cancer
Intervention: Drug: lapatinib + capecitabine
78 Completed
GR270773 In The Treatment Of Suspected Or Confirmed Gram-Negative Severe Sepsis In Adults
Condition: Sepsis
Intervention: Drug: Intravenous GR270773- Phospholipid Emulsion
79 Active, not recruiting
Prevention of Recurrence of Diverticulitis
Condition: Diverticulitis
Interventions: Drug: SPD476, MMX™ mesalazine, 1.2g extended release tablet; Drug: placebo
80 Completed
Has Results
PRoFESS – Prevention Regimen For Effectively Avoiding Second Strokes
Condition: Cerebrovascular Accident
Interventions: Drug: extended-release dipyridamole + aspirin; Drug: clopidogrel; Drug: telmisartan